Drugmakers Say Pacific Trade Agreement to Stifle Investment

Updated on
  • Pact likely to set off intense lobbying in Washington
  • Other critics say deal hurts access to drugs in poor nations

Pacific-Rim Nations Agree to Pact to Cut Trade Barriers

The biotechnology industry criticized the deal struck by negotiators for the Trans-Pacific Partnership agreement, saying it would undermine innovation by offering only limited protection of the data that drugmakers keep secret from competitors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.